The relationships between cardiovascular disease and diabetes: Focus on pathogenesis

Endocrinology and Metabolism Clinics of North America

Volumn 43, Issue 1, 2014, Pages 41-57

  Kovacic, Jason C ^a   Castellano, Jose M ^a   Farkouh, Michael E ^a,b   Fuster, Valentin ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Cardiovascular disease; Diabetes; Diabetic cardiomyopathy; Obesity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PACLITAXEL; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; TRANDOLAPRIL PLUS VERAPAMIL;

ATHEROGENESIS; AUTONOMIC NEUROPATHY; CARDIAC AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DRUG ELUTING STENT; DRUG MEGADOSE; DYSLIPIDEMIA; EXERCISE; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING CESSATION; STEM CELL; UNSPECIFIED SIDE EFFECT; VASCULAR PROGENITOR CELL; WEIGHT CHANGE; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; ECONOMICS; PATHOPHYSIOLOGY;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS;

EID: 84896855805     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.09.007     Document Type: Review

References (74)

1. King H., Aubert R.E., Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Boyle J.P., Honeycutt A.A., Narayan K.M., et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001, 24:1936-1940.
3. New WHO statistics highlight increases in blood pressure and diabetes, other noncommunicable risk factors. Cent Eur J Public Health 2012, 20(134):149.
4. Chiha M., Njeim M., Chedrawy E.G. Diabetes and coronary heart disease: a risk factor for the global epidemic. Int J Hypertens 2012, 2012:697240.
5. Tillquist M.N., Maddox T.M. Update on diabetic cardiomyopathy: inches forward, miles to go. Curr Diab Rep 2012, 12:305-313.
6. Johnson P.C., Doll S.C., Cromey D.W. Pathogenesis of diabetic neuropathy. Ann Neurol 1986, 19:450-457.
7. Weil E.J., Lemley K.V., Mason C.C., et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int 2012, 82:1010-1017.
8. Tang Y., Li G.D. Chronic exposure to high glucose impairs bradykinin-stimulated nitric oxide production by interfering with the phospholipase-C-implicated signalling pathway in endothelial cells: evidence for the involvement of protein kinase C. Diabetologia 2004, 47:2093-2104.
9. Kovacic J.C., Martin A., Carey D., et al. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antivir Ther 2005, 10:135-143.
10. Schaffer S.W., Jong C.J., Mozaffari M. Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vascul Pharmacol 2012, 57:139-149.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
12. Kovacic J.C., Moreno P., Nabel E.G., et al. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation 2011, 123:1900-1910.
13. Konova E., Baydanoff S., Atanasova M., et al. Age-related changes in the glycation of human aortic elastin. Exp Gerontol 2004, 39:249-254.
14. Kislinger T., Fu C., Huber B., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. JBiol Chem 1999, 274:31740-31749.
15. Brett J., Schmidt A.M., Yan S.D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993, 143:1699-1712.
16. Giri R., Shen Y., Stins M., et al. beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 2000, 279:C1772-C1781.
17. Kunt T., Forst T., Harzer O., et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998, 106:183-188.
18. Otero K., Martinez F., Beltran A., et al. Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells. Biochem J 2001, 359:567-574.
19. Svensjo E., Cyrino F., Michoud E., et al. Vascular permeability increase as induced by histamine or bradykinin is enhanced by advanced glycation endproducts (AGEs). JDiabet Complications 1999, 13:187-190.
20. Bucala R., Tracey K.J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. JClin Invest 1991, 87:432-438.
21. Scheubel R.J., Kahrstedt S., Weber H., et al. Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes. Exp Gerontol 2006, 41:540-548.
22. Xiang M., Yang M., Zhou C., et al. Crocetin prevents AGEs-induced vascular endothelial cell apoptosis. Pharmacol Res 2006, 54:268-274.
23. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
24. Muris D.M., Houben A.J., Schram M.T., et al. Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 2012, 32:3082-3094.
25. Kovacic J.C., Fuster V. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. Mt Sinai J Med 2012, 79:664-673.
26. Centers for Disease Control and Prevention. Leading causes of death reports. Available at:. Accessed May 19, 2011. http://webappa.cdc.gov/sasweb/ncipc/leadcaus10.html.
27. Beeri M.S., Silverman J.M., Davis K.L., et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. JGerontol A Biol Sci Med Sci 2005, 60:471-475.
28. Nelson P.T., Smith C.D., Abner E.A., et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 2009, 1792:454-469.
29. Kovacic J.C., Moore J., Herbert A., et al. Endothelial progenitor cells, angioblasts, and angiogenesis-old terms reconsidered from a current perspective. Trends Cardiovasc Med 2008, 18:45-51.
30. Tepper O.M., Galiano R.D., Capla J.M., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786.
31. Spinetti G., Cordella D., Fortunato O., et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 2013, 112:510-522.
32. Parathath S., Grauer L., Huang L.S., et al. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 2011, 60:1759-1769.
33. Kini A., Baber U., Kovacic J.C., et al. Impact of diabetes mellitus on atherosclerotic plaque lipid regression: results from the prospective. Randomized YELLOW Trial Circulation 2012, 126:A17291.
34. Mather K.J., Steinberg H.O., Baron A.D. Insulin resistance in the vasculature. JClin Invest 2013, 123:1003-1004.
35. Rubler S., Dlugash J., Yuceoglu Y.Z., et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30:595-602.
36. Fang Z.Y., Prins J.B., Marwick T.H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004, 25:543-567.
37. Voulgari C., Papadogiannis D., Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010, 6:883-903.
38. Movahed M.R., Hashemzadeh M., Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005, 105:315-318.
39. Maisch B., Alter P., Pankuweit S. Diabetic cardiomyopathy-fact or fiction?. Herz 2011, 36:102-115.
40. Singh G.B., Sharma R., Khullar M. Epigenetics and diabetic cardiomyopathy. Diabetes Res Clin Pract 2011, 94:14-21.
41. Avendano G.F., Agarwal R.K., Bashey R.I., et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999, 48:1443-1447.
42. Cesario D.A., Brar R., Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006, 35:601-610. ix-x.
43. Falcao-Pires I., Leite-Moreira A.F. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 2012, 17:325-344.
44. Aneja A., Tang W.H., Bansilal S., et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008, 121:748-757.
45. Park T.S., Hu Y., Noh H.L., et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. JLipid Res 2008, 49:2101-2112.
46. Yazaki Y., Isobe M., Takahashi W., et al. Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course. Heart 1999, 81:153-159.
47. Peti-Peterdi J., Kang J.J., Toma I. Activation of the renal renin-angiotensin system in diabetes-new concepts. Nephrol Dial Transplant 2008, 23:3047-3049.
48. Kawasaki D., Kosugi K., Waki H., et al. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients-reversal by chronic angiotensin II type 1A receptor blockade. Circ J 2007, 71:524-529.
49. Mytas D.Z., Stougiannos P.N., Zairis M.N., et al. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. JDiabet Complications 2009, 23:273-282.
50. Asbun J., Villarreal F.J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. JAm Coll Cardiol 2006, 47:693-700.
51. Boyer J.K., Thanigaraj S., Schechtman K.B., et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 2004, 93:870-875.
52. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. JAm Soc Echocardiogr 2005, 18:1440-1463.
53. Chung J., Abraszewski P., Yu X., et al. Paradoxical increase in ventricular torsion and systolic torsion rate in type I diabetic patients under tight glycemic control. JAm Coll Cardiol 2006, 47:384-390.
54. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. JAm Coll Cardiol 2006, 48:1548-1551.
55. Kiencke S., Handschin R., von Dahlen R., et al. Pre-clinical diabetic cardiomyopathy: prevalence, screening, and outcome. Eur J Heart Fail 2010, 12:951-957.
56. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. JAm Coll Cardiol 2010, 55:300-305.
57. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66.
58. Puccetti L., Santilli F., Pasqui A.L., et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 2011, 214:122-128.
59. Group A.S., Ginsberg H.N., Elam M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. NEngl J Med 2010, 362:1563-1574.
60. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
61. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. NEngl J Med 2012, 367:2089-2099.
62. Investigators A.H., Boden W.E., Probstfield J.L., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365:2255-2267.
63. Reboldi G., Gentile G., Angeli F., et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. JHypertens 2011, 29:1253-1269.
64. Cooper-DeHoff R.M., Gong Y., Handberg E.M., et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010, 304:61-68.
65. Macisaac R.J., Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Heart Lung Circ 2011, 20:647-654.
66. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
67. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:e2-e220.
68. Smith S.C., Faxon D., Cascio W., et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group VI: revascularization in diabetic patients. Circulation 2002, 105:e165-e169.
69. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. NEngl J Med 1996, 335:217-225.
70. Serruys P.W., Ong A.T., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. JAm Coll Cardiol 2005, 46:575-581.
71. Mohr F.W., Morice M.C., Kappetein A.P., et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013, 381:629-638.
72. Farkouh M.E., Domanski M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. NEngl J Med 2012, 367:2375-2384.
73. Sianos G., Morel M.A., Kappetein A.P., et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1:219-227.
74. Hlatky M.A., Boothroyd D.B., Bravata D.M., et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009, 373:1190-1197.